SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors

Tools

Xue, Wei, Brentville, Victoria A., Symonds, Peter, Cook, Katherine, Yagita, Hideo, Metheringham, Rachael L. and Durrant, Lindy (2016) SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors. Oncotarget, 7 (50). pp. 83088-83100. ISSN 1949-2553

Full text not available from this repository.

Abstract

Purpose: We have previously shown that supraoptimal signaling of high avidity T cells leads to high expression of PD-1 and inhibition of proliferation. This study was designed to see if this effect could be mitigated by combining a vaccine that stimulates high avidity T cells with PD-1 blockade.

Experimental Design: We investigated the anti-tumor effect of a huIgG1 antibody DNA vaccine (SCIB1) and PD-1 blockade.

Results: Vaccination of HLA-DR4 transgenic mice with SCIB1 induced high frequency and avidity T cell responses that resulted in survival (40%) of mice with established B16F1-DR4 tumors. SCIB1 vaccination was associated with increased infiltration of CD4 and CD8 T cells within the tumor but was also associated with upregulation of PD-L1 within the tumor environment. PD-1 blockade also resulted in increased CD8 T cell infiltration and an anti-tumor response with 50% of mice showing long term survival. In line with our hypothesis that PD-1/PD-L1 signaling results in inhibition of proliferation of high avidity T cells at the tumor site, the combination of PD-1 blockade with vaccination, enhanced the number and proliferation of the CD8 tumor infiltrate. This resulted in a potent anti-tumor response with 80% survival of the mice.

Conclusions: There is a benefit in combining PD-1 blockade with vaccines that induce high avidity T cell responses and in particular with SCIB1.

Item Type: Article
RIS ID: https://nottingham-repository.worktribe.com/output/830080
Keywords: DNA vaccine; Fc targeting; PD-1 blockade; melanoma; tumor rejection
Schools/Departments: University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Division of Cancer and Stem Cells
Identification Number: 10.18632/oncotarget.13070
Depositing User: Durrant, Lindy
Date Deposited: 15 Feb 2018 08:56
Last Modified: 04 May 2020 18:22
URI: https://eprints.nottingham.ac.uk/id/eprint/49786

Actions (Archive Staff Only)

Edit View Edit View